New combo aims to tackle Hard-to-Treat colorectal cancer
NCT ID NCT07229872
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a combination of two drugs—aipalolitovorelizumab and fruquintinib—in 18 people with advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if the combo can shrink tumors or slow the disease. Participants will receive the drugs in 3-week cycles until the cancer progresses or side effects become too severe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- aipalolitovorelizumab (QL1706) and fruquintinib
- What this could lead to
- If this combination works, it could offer a new treatment option for people with advanced colorectal cancer who have run out of standard therapies.
- What could go wrong
- This is a very small, early-phase trial with only 18 participants, so results may not apply to everyone. The drugs may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?